Skip to main content

and
  1. No Access

    Article

    Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

    In patients with relapsed or refractory (r/r) acute myeloid leukemia (AML), long-term disease control can only be achieved by allogeneic hematopoietic stem cell transplantation (HSCT). We studied the safety an...

    J M Middeke, R Herbst, S Parmentier, G Bug, M Hänel, G Stuhler in Leukemia (2016)

  2. Article

    Open Access

    Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

    This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34+ blood cells to pre-empt relapse in patients with CD34+ myelodysplastic s...

    U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani, I-M Klut in Leukemia (2012)

  3. No Access

    Article

    Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia

    F A Fierro, S Brenner, U Oelschlaegel, A Jacobi, H Knoth, G Ehninger, T Illmer in Leukemia (2009)

  4. No Access

    Article

    Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation

    A Jenke, J Freiberg-Richter, C Johne, H Knoth, E Schleyer in Bone Marrow Transplantation (2005)